Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is assess the efficacy and safety of topical hydrocortisone
(Softacort) for treatment of clinical signs and symptoms of dry eye disease when associated
with moderate meibomian gland dysfunction.